Literature DB >> 12511526

Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor?

Andrei Forclaz1, Marc Maillard, Jürg Nussberger, Hans R Brunner, Michel Burnier.   

Abstract

We assessed the blockade of the renin-angiotensin system (RAS) achieved with 2 angiotensin (Ang) antagonists given either alone at different doses or with an ACE inhibitor. First, 20 normotensive subjects were randomly assigned to 100 mg OD losartan (LOS) or 80 mg OD telmisartan (TEL) for 1 week; during another week, the same doses of LOS and TEL were combined with 20 mg OD lisinopril. Then, 10 subjects were randomly assigned to 200 mg OD LOS and 160 mg OD TEL for 1 week and 100 mg BID LOS and 80 mg BID TEL during the second week. Blockade of the RAS was evaluated with the inhibition of the pressor effect of exogenous Ang I, an ex vivo receptor assay, and the changes in plasma Ang II. Trough blood pressure response to Ang I was blocked by 35+/-16% (mean+/-SD) with 100 mg OD LOS and by 36+/-13% with 80 mg OD TEL. When combined with lisinopril, blockade was 76+/-7% with LOS and 79+/-9% with TEL. With 200 mg OD LOS, trough blockade was 54+/-14%, but with 100 mg BID it increased to 77+/-8% (P<0.01). Telmisartan (160 mg OD and 80 mg BID) produced a comparable effect. Thus, at their maximal recommended doses, neither LOS nor TEL blocks the RAS for 24 hours; hence, the addition of an ACE inhibitor provides an additional blockade. A 24-hour blockade can be achieved with an angiotensin antagonist alone, provided higher doses or a BID regimen is used.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12511526     DOI: 10.1161/01.hyp.0000047512.58862.a9

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  16 in total

Review 1.  Are two better than one? Angiotensin-converting enzyme inhibitors plus angiotensin receptor blockers for reducing blood pressure and proteinuria in kidney disease.

Authors:  Stuart L Linas
Journal:  Clin J Am Soc Nephrol       Date:  2008-01       Impact factor: 8.237

2.  Efficacy of aliskiren, compared with angiotensin II blockade, in slowing the progression of diabetic nephropathy in db/db mice: should the combination therapy be a focus?

Authors:  Guangyu Zhou; Xia Liu; Alfred K Cheung; Yufeng Huang
Journal:  Am J Transl Res       Date:  2015-05-15       Impact factor: 4.060

Review 3.  Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination.

Authors:  Francesca Cagnoni; Christian Achiri Ngu Njwe; Augusto Zaninelli; Alessandra Rossi Ricci; Diletta Daffra; Antonio D'Ospina; Paola Preti; Maurizio Destro
Journal:  Vasc Health Risk Manag       Date:  2010-08-09

Review 4.  The effect of RAAS blockade on the progression of diabetic nephropathy.

Authors:  Sara S Roscioni; Hiddo J Lambers Heerspink; Dick de Zeeuw
Journal:  Nat Rev Nephrol       Date:  2013-12-03       Impact factor: 28.314

5.  An additive effect of eplerenone to ACE inhibitor on slowing the progression of diabetic nephropathy in the db/db mice.

Authors:  Guangyu Zhou; Ulrika Johansson; Xiao-Rong Peng; Krister Bamberg; Yufeng Huang
Journal:  Am J Transl Res       Date:  2016-03-15       Impact factor: 4.060

Review 6.  Telmisartan/hydrochlorothiazide: in the treatment of essential hypertension.

Authors:  Caroline Fenton; Gillian M Keating; Lesley J Scott
Journal:  Drugs       Date:  2003       Impact factor: 9.546

7.  Anti-diabetic and renoprotective effects of aliskiren in streptozotocin-induced diabetic nephropathy in female rats.

Authors:  Amal M Mahfoz; Hekma A Abd El-Latif; Lamiaa A Ahmed; Nahed M Hassanein; Afaf A Shoka
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-09-09       Impact factor: 3.000

Review 8.  How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy?

Authors:  Marc S Weinberg; Nicholas Kaperonis; George L Bakris
Journal:  Curr Hypertens Rep       Date:  2003-10       Impact factor: 5.369

9.  Potential of Renin-Angiotensin-Aldosterone System Modulations in Diabetic Kidney Disease: Old Players to New Hope!

Authors:  Vajir Malek; Sachin V Suryavanshi; Nisha Sharma; Yogesh A Kulkarni; Shrikant R Mulay; Anil Bhanudas Gaikwad
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

Review 10.  Functional renin receptors in renal mesangial cells.

Authors:  Yufeng Huang; Wayne A Border; Nancy A Noble
Journal:  Curr Hypertens Rep       Date:  2007-04       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.